Nrf2-inducing anti-oxidation stress response in the rat liver - New beneficial effect of lansoprazole

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Yamashita, Yasunobu ^a   Ueyama, Takashi ^a   Nishi, Toshio ^a   Yamamoto, Yuta ^a   Kawakoshi, Akatsuki ^a   Sunami, Shogo ^a   Iguchi, Mikitaka ^a   Tamai, Hideyuki ^a   Ueda, Kazuki ^a   Ito, Takao ^a   Tsuruo, Yoshihiro ^a   Ichinose, Masao ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A1; GLUCURONOSYLTRANSFERASE 1A6; GLUTATHIONE TRANSFERASE A2; HEME OXYGENASE 1; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LANSOPRAZOLE; MESSENGER RNA; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; TRANSCRIPTION FACTOR NRF2; ANTIOXIDANT; NFE2L2 PROTEIN, RAT; THIOACETAMIDE;

AHR GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL FRACTIONATION; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; CYP1A1 GENE; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; GENE; GENE EXPRESSION; GSTA2 GENE; HO 1 GENE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KEAP1 GENE; LIVER; LIVER CELL NUCLEUS; LIVER INJURY; MALE; MICROARRAY ANALYSIS; NONHUMAN; NQO1 GENE; NRF2 GENE; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PPAR ALPHA GENE; PROTEIN TRANSPORT; RAT; UGT1A6 GENE; UPREGULATION; WESTERN BLOTTING; ACTIVE TRANSPORT; ANIMAL; CELL NUCLEUS; DOSE RESPONSE; DRUG EFFECTS; LIVER CELL; METABOLISM; PATHOLOGY; TOXICITY; WISTAR RAT;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTIOXIDANTS; CELL NUCLEUS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATOCYTES; LANSOPRAZOLE; LIVER; MALE; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; RATS; RATS, WISTAR; THIOACETAMIDE; UP-REGULATION;

EID: 84901355689     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097419     Document Type: Article

References (34)

1. Stedman CA, Barclay ML (2000) Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 14:963-978. (Pubitemid 30618157)
2. Bown RL (2002) An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole. Int J Clin Pract 56:132-139.
3. Satoh H (2013) Discovery of lansoprazole and its unique pharmacological properties independent from anti-secretory activity. Curr Pharm Des 19:67-75.
4. Murakami I, Satoh H, Asano S, Maeda R (1996) Role of capsaicin-sensitive sensory neurons and nitric oxide in the protective effect of lansoprazole, a proton pump inhibitor, on the gastric mucosa in rats. Jpn J Pharmacol 72:137-147. (Pubitemid 26390724)
5. Becker JC, Grosser N, Waltke C, Schulz S, Erdmann K, et al. (2006) Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells. Biochem Biophys Res Commun 345:1014-1021. (Pubitemid 43776514)
6. Takagi T, Naito Y, Okada H, Ishii T, Mizushima K, et al. (2009) Lansoprazole, a proton pump inhibitor, mediates anti-inflammatory effect in gastric mucosal cells through the induction of heme oxygenase-1 via activation of NF-E2-related factor 2 and oxidation of kelch-like ECH-associating protein 1. J Pharmacol Exp Ther 331:255-264. doi: 10.1124/jpet.109.152702.
7. Yoda Y, Amagase K, Kato S, Tokioka S, Murano M, et al. (2010) Prevention by lansoprazole, a proton pump inhibitor, of indomethacin -induced small intestinal ulceration in rats through induction of heme oxygenase-1. J Physiol Pharmacol 61:287-294.
8. Otterbein LE, Choi AM (2000) Heme oxygenase: colors of defense against cellular stress. Am J Physiol Lung Cell Mol Physiol 279:L1029-L1037. (Pubitemid 32009488)
9. Hayes JD, McMahon M, Chowdhry S, Dinkova-Kostova AT (2010) Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal 13:1713-1748. doi: 10.1089/ars.2010.3221.
10. Copple IM (2012) The Keap1-Nrf2 cell defense pathway-a promising therapeutic target? Adv Pharmacol 63:43-79. doi: 10.1016/B978-0-12-398339-8. 00002-1.
11. Zenkov NK, Menshchikova EB, Tkachev VO (2013) Keap1/Nrf2/ARE redox-sensitive signaling system as a pharmacological target. Biochemistry (Mosc) 78:19-36. doi: 10.1134/S0006297913010033.
12. Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD, Kang MI, Kobayashi A, et al. (2004) Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc Natl Acad Sci USA 101:2040-2045. (Pubitemid 38229011)
13. Eggler AL, Gay KA, Mesecar AD (2008) Molecular mechanisms of natural products in chemoprevention: induction of cytoprotective enzymes by Nrf2. Mol Nutr Food Res 52 Suppl 1:S84-94. doi: 10.1002/mnfr.200700249.
14. Numazawa S, Ishikawa M, Yoshida A, Tanaka S, Yoshida T (2003) Atypical protein kinase C mediates activation of NF-E2-related factor 2 in response to oxidative stress. Am J Physiol Cell Physiol 285:C334-C342. (Pubitemid 36917848)
15. Tkachev VO, Menshchikova EB, Zenkov NK (2011) Mechanism of the Nrf2/Keap1/ARE signaling system. Biochemistry (Mosc) 76:407-422.
16. Keum YS (2011) Regulation of the Keap1/Nrf2 system by chemopreventive sulforaphane: implications of posttranslational modifications. Ann NY Acad Sci 1229:184-189. doi: 10.1111/j.1749-6632.2011.06092.x.
17. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM (2009) Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta. 1790:1149-1160. doi: 10.1016/j.bbagen.2009.07.026.
18. Hayes JD, McMahon M (2001) Molecular basis for the contribution of the antioxidant responsive element to cancer chemoprevention. Cancer Lett 174:103-113. (Pubitemid 33026113)
19. Kawai H, Kudo N, Kawashima Y, Mitsumoto A (2009) Efficacy of urine bile acid as a non-invasive indicator of liver damage in rats. J Toxicol Sci 34:27-38.
20. Ueda K, Ueyama T, Oka M, Ito T, Tsuruo Y, et al. (2009) Polaprezinc (Zinc L-carnosine) is a potent inducer of anti-oxidative stress enzyme, heme oxygenase (HO)-1 - a new mechanism of gastric mucosal protection. J Pharmacol Sci 110:285-294.
21. Yamamoto Y, Tanahashi T, Kawai T, Chikahisa S, Katsuura S, et al. (2009) Changes in behavior and gene expression induced by caloric restriction in C57BL/6 mice. Physiol Genomics 39:227-235.
22. Ueyama T, Yamamoto Y, Ueda K, Yajima A, Maeda Y, et al. (2013) Is gastrectomy-induced high turnover of bone with hyperosteoidosis and increase of mineralization a typical osteomalacia? PLoS One 11;8:e65685. doi: 10.1371/journal.pone.0065685.
23. Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A (1996) Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 277:805-816. (Pubitemid 27168992)
24. Curi-Pedrosa R, Daujat M, Pichard L, Ourlin JC, Clair P, et al. (1994) Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J Pharmacol Exp Ther 269:384-392. (Pubitemid 24143278)
25. Masubuchi N, Hakusui H, Okazaki O (1997) Effects of pantoprazole on xenobiotic metabolizing enzymes in rat liver microsomes: a comparison with other proton pump inhibitors. Drug Metab Dispos 25:584-589. (Pubitemid 27213099)
26. Yoshinari K, Ueda R, Kusano K, Yoshimura T, Nagata K, et al. (2008) Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements. Biochem Pharmacol 76:139-145. doi: 10.1016/j.bcp.2008.04.005.
27. Rushmore TH, Kong AN (2002) Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr Drug Metab 3:481-490. (Pubitemid 34987481)
28. Miao W, Hu L, Scrivens PJ, Batist G (2005) Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: direct cross-talk between phase I and II drug-metabolizing enzymes. J Biol Chem 280:20340-20348. (Pubitemid 40776732)
29. Shin S, Wakabayashi N, Misra V, Biswal S, Lee GH, et al. (2007) NRF2 modulates aryl hydrocarbon receptor signaling: influence on adipogenesis. Mol Cell Biol 27:7188-7197. (Pubitemid 47549754)
30. Whitlock JP Jr (1990) Genetic and molecular aspects of 2,3,7,8-tetrachlorodi-benzo-p-dioxin action. Annu Rev Pharmacol Toxicol 30:251-277.
31. Yeager RL, Reisman SA, Aleksunes LM, Klaassen CD (2009) Introducing the "TCDD-inducible AhR-Nrf2 gene battery". Toxicol Sci 111:238-246. doi: 10.1093/toxsci/kfp115.
32. Sanderson LM, Boekschoten MV, Desvergne B, Müller M, Kersten S (2010) Transcriptional profiling reveals divergent roles of PPARalpha and PPARbeta/delta in regulation of gene expression in mouse liver. Physiol Genomics 41:42-52. doi: 10.1152/physiolgenomics.00127.2009.
33. Ueda K, Ueyama T, Yoshida K, Kimura H, Ito T, et al. (2008) Adaptive HNE-Nrf2-HO-1 pathway against oxidative stress is associated with acute gastric mucosal lesions. Am J Physiol 295:G460-G469.
34. Inatomi N, Murakami I, Asano S, Sato H (1997) Effect of lansoprazole and rabeprazole (E-3810) on gastric acid secretion and experimental ulcers in rats. (in Japanese) Jpn Pharmacol Ther 25:2445-2454.